Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma Article Swipe
Mateo Mejía Saldarriaga
,
Darren Pan
,
Caitlin Unkenholz
,
Tarek H. Mouhieddine
,
Juan Esteban Velez-Hernandez
,
Katherine Engles
,
Joshua Fein
,
Jorge Monge
,
Cara A. Rosenbaum
,
Roger Pearse
,
David Jayabalan
,
Christian Gordillo
,
Hei Ton Chan
,
Samuel Yamshon
,
Santiago Thibaud
,
Markus Y. Mapara
,
Giorgio Inghirami
,
Suzanne Lentzsch
,
Ran Reshef
,
Adriana Rossi
,
Samir Parekh
,
Sundar Jagannath
,
Shambavi Richard
,
Rubén Niesvizky
,
Mark Bustoros
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1182/bloodadvances.2023012470
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1182/bloodadvances.2023012470
B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor T cells (CAR-Ts) used in multiple myeloma (MM) are rapidly becoming a mainstay in the treatment of relapsed/refractory (R/R) disease, and CAR-T expansion after infusion has been shown to inform depth and duration of response (DoR), but measuring this process remains investigational. This multicenter study describes the kinetics and prognostic impact of absolute lymphocyte count (ALC) in the first 15 days after CAR-T infusion in 156 patients with relapsed MM treated with the BCMA-targeting agents ciltacabtagene autoleucel and idecabtagene vicleucel. Patients with higher maximum ALC (ALCmax) had better depth of response, progression-free survival (PFS), and DoR. Patients with ALCmax >1.0 × 103/μL had a superior PFS (30.5 months vs 6 months; P < .001) compared with those with ≤1.0 × 103/μL, whereas patients with ALCmax ≤0.5 × 103/μL represent a high-risk group with early disease progression and short PFS (hazard ratio, 3.4; 95% confidence interval, 2-5.8; P < .001). In multivariate analysis, ALCmax >1.0 × 103/μL and nonparaskeletal extramedullary disease were the only independent predictors of PFS and DoR after accounting for international staging systemic staging, age, CAR-T product, high-risk cytogenetics, and the number of previous lines. Moreover, our flow cytometry data suggest that ALC is a surrogate for BCMA CAR-T expansion and can be used as an accessible prognostic marker. We report, to our knowledge, for the first time the association of ALC after BCMA CAR-T infusion with clinical outcomes and its utility in predicting response in patients with R/R MM.
Related Topics
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1182/bloodadvances.2023012470
- OA Status
- gold
- Cited By
- 14
- References
- 19
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4398197746
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4398197746Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1182/bloodadvances.2023012470Digital Object Identifier
- Title
-
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-05-22Full publication date if available
- Authors
-
Mateo Mejía Saldarriaga, Darren Pan, Caitlin Unkenholz, Tarek H. Mouhieddine, Juan Esteban Velez-Hernandez, Katherine Engles, Joshua Fein, Jorge Monge, Cara A. Rosenbaum, Roger Pearse, David Jayabalan, Christian Gordillo, Hei Ton Chan, Samuel Yamshon, Santiago Thibaud, Markus Y. Mapara, Giorgio Inghirami, Suzanne Lentzsch, Ran Reshef, Adriana Rossi, Samir Parekh, Sundar Jagannath, Shambavi Richard, Rubén Niesvizky, Mark BustorosList of authors in order
- Landing page
-
https://doi.org/10.1182/bloodadvances.2023012470Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1182/bloodadvances.2023012470Direct OA link when available
- Concepts
-
Multiple myeloma, Oncology, Medicine, Internal medicine, LymphocyteTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
14Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 13, 2024: 1Per-year citation counts (last 5 years)
- References (count)
-
19Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4398197746 |
|---|---|
| doi | https://doi.org/10.1182/bloodadvances.2023012470 |
| ids.doi | https://doi.org/10.1182/bloodadvances.2023012470 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38776397 |
| ids.openalex | https://openalex.org/W4398197746 |
| fwci | 7.52845436 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000628 |
| mesh[1].descriptor_ui | D009101 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | therapy |
| mesh[1].descriptor_name | Multiple Myeloma |
| mesh[2].qualifier_ui | Q000401 |
| mesh[2].descriptor_ui | D009101 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | mortality |
| mesh[2].descriptor_name | Multiple Myeloma |
| mesh[3].qualifier_ui | Q000175 |
| mesh[3].descriptor_ui | D009101 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | diagnosis |
| mesh[3].descriptor_name | Multiple Myeloma |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D053301 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | B-Cell Maturation Antigen |
| mesh[5].qualifier_ui | Q000009 |
| mesh[5].descriptor_ui | D016219 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | adverse effects |
| mesh[5].descriptor_name | Immunotherapy, Adoptive |
| mesh[6].qualifier_ui | Q000379 |
| mesh[6].descriptor_ui | D016219 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | methods |
| mesh[6].descriptor_name | Immunotherapy, Adoptive |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D008297 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Male |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D005260 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Female |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D008875 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Middle Aged |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D018655 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Lymphocyte Count |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D000368 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Aged |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D011379 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Prognosis |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D016896 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Treatment Outcome |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D000328 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Adult |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D000076962 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Receptors, Chimeric Antigen |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D006801 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Humans |
| mesh[17].qualifier_ui | Q000628 |
| mesh[17].descriptor_ui | D009101 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | therapy |
| mesh[17].descriptor_name | Multiple Myeloma |
| mesh[18].qualifier_ui | Q000401 |
| mesh[18].descriptor_ui | D009101 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | mortality |
| mesh[18].descriptor_name | Multiple Myeloma |
| mesh[19].qualifier_ui | Q000175 |
| mesh[19].descriptor_ui | D009101 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | diagnosis |
| mesh[19].descriptor_name | Multiple Myeloma |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D053301 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | B-Cell Maturation Antigen |
| mesh[21].qualifier_ui | Q000009 |
| mesh[21].descriptor_ui | D016219 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | adverse effects |
| mesh[21].descriptor_name | Immunotherapy, Adoptive |
| mesh[22].qualifier_ui | Q000379 |
| mesh[22].descriptor_ui | D016219 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | methods |
| mesh[22].descriptor_name | Immunotherapy, Adoptive |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D008297 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Male |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D005260 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Female |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D008875 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Middle Aged |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D018655 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Lymphocyte Count |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D000368 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Aged |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D011379 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Prognosis |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D016896 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Treatment Outcome |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D000328 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Adult |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D000076962 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Receptors, Chimeric Antigen |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D006801 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Humans |
| mesh[33].qualifier_ui | Q000628 |
| mesh[33].descriptor_ui | D009101 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | therapy |
| mesh[33].descriptor_name | Multiple Myeloma |
| mesh[34].qualifier_ui | Q000401 |
| mesh[34].descriptor_ui | D009101 |
| mesh[34].is_major_topic | True |
| mesh[34].qualifier_name | mortality |
| mesh[34].descriptor_name | Multiple Myeloma |
| mesh[35].qualifier_ui | Q000175 |
| mesh[35].descriptor_ui | D009101 |
| mesh[35].is_major_topic | True |
| mesh[35].qualifier_name | diagnosis |
| mesh[35].descriptor_name | Multiple Myeloma |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D053301 |
| mesh[36].is_major_topic | True |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | B-Cell Maturation Antigen |
| mesh[37].qualifier_ui | Q000009 |
| mesh[37].descriptor_ui | D016219 |
| mesh[37].is_major_topic | True |
| mesh[37].qualifier_name | adverse effects |
| mesh[37].descriptor_name | Immunotherapy, Adoptive |
| mesh[38].qualifier_ui | Q000379 |
| mesh[38].descriptor_ui | D016219 |
| mesh[38].is_major_topic | True |
| mesh[38].qualifier_name | methods |
| mesh[38].descriptor_name | Immunotherapy, Adoptive |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D008297 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Male |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D005260 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Female |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D008875 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Middle Aged |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D018655 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Lymphocyte Count |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D000368 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Aged |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D011379 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Prognosis |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D016896 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Treatment Outcome |
| mesh[46].qualifier_ui | |
| mesh[46].descriptor_ui | D000328 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | |
| mesh[46].descriptor_name | Adult |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D000076962 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | Receptors, Chimeric Antigen |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D006801 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Humans |
| mesh[49].qualifier_ui | Q000628 |
| mesh[49].descriptor_ui | D009101 |
| mesh[49].is_major_topic | True |
| mesh[49].qualifier_name | therapy |
| mesh[49].descriptor_name | Multiple Myeloma |
| type | article |
| title | Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma |
| biblio.issue | 15 |
| biblio.volume | 8 |
| biblio.last_page | 3869 |
| biblio.first_page | 3859 |
| topics[0].id | https://openalex.org/T11491 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | CAR-T cell therapy research |
| topics[1].id | https://openalex.org/T10649 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9998999834060669 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2720 |
| topics[1].subfield.display_name | Hematology |
| topics[1].display_name | Multiple Myeloma Research and Treatments |
| topics[2].id | https://openalex.org/T10185 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9984999895095825 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2734 |
| topics[2].subfield.display_name | Pathology and Forensic Medicine |
| topics[2].display_name | Lymphoma Diagnosis and Treatment |
| is_xpac | False |
| apc_list.value | 3000 |
| apc_list.currency | USD |
| apc_list.value_usd | 3000 |
| apc_paid.value | 3000 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3000 |
| concepts[0].id | https://openalex.org/C2776364478 |
| concepts[0].level | 2 |
| concepts[0].score | 0.7930137515068054 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q467635 |
| concepts[0].display_name | Multiple myeloma |
| concepts[1].id | https://openalex.org/C143998085 |
| concepts[1].level | 1 |
| concepts[1].score | 0.594942033290863 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[1].display_name | Oncology |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.5704764723777771 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.5697219371795654 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C2777761686 |
| concepts[4].level | 2 |
| concepts[4].score | 0.4763118028640747 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q715347 |
| concepts[4].display_name | Lymphocyte |
| keywords[0].id | https://openalex.org/keywords/multiple-myeloma |
| keywords[0].score | 0.7930137515068054 |
| keywords[0].display_name | Multiple myeloma |
| keywords[1].id | https://openalex.org/keywords/oncology |
| keywords[1].score | 0.594942033290863 |
| keywords[1].display_name | Oncology |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.5704764723777771 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.5697219371795654 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/lymphocyte |
| keywords[4].score | 0.4763118028640747 |
| keywords[4].display_name | Lymphocyte |
| language | en |
| locations[0].id | doi:10.1182/bloodadvances.2023012470 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2764683450 |
| locations[0].source.issn | 2473-9529, 2473-9537 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2473-9529 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Blood Advances |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_lineage_names | Elsevier BV |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Blood Advances |
| locations[0].landing_page_url | https://doi.org/10.1182/bloodadvances.2023012470 |
| locations[1].id | pmid:38776397 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Blood advances |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38776397 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:11321283 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Blood Adv |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11321283 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5035797566 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3504-5597 |
| authorships[0].author.display_name | Mateo Mejía Saldarriaga |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[0].affiliations[0].raw_affiliation_string | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[0].institutions[0].id | https://openalex.org/I205783295 |
| authorships[0].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Cornell University |
| authorships[0].institutions[1].id | https://openalex.org/I4387153466 |
| authorships[0].institutions[1].ror | https://ror.org/02r109517 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[0].institutions[1].country_code | US |
| authorships[0].institutions[1].display_name | Weill Cornell Medicine |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Mateo Mejia Saldarriaga |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[1].author.id | https://openalex.org/A5022621152 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-1668-9829 |
| authorships[1].author.display_name | Darren Pan |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[1].affiliations[0].raw_affiliation_string | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[1].institutions[0].id | https://openalex.org/I98704320 |
| authorships[1].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Darren Pan |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[2].author.id | https://openalex.org/A5048614389 |
| authorships[2].author.orcid | https://orcid.org/0009-0005-8972-7883 |
| authorships[2].author.display_name | Caitlin Unkenholz |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[2].affiliations[0].raw_affiliation_string | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[2].institutions[0].id | https://openalex.org/I205783295 |
| authorships[2].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Cornell University |
| authorships[2].institutions[1].id | https://openalex.org/I4387153466 |
| authorships[2].institutions[1].ror | https://ror.org/02r109517 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | Weill Cornell Medicine |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Caitlin Unkenholz |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[3].author.id | https://openalex.org/A5054484092 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-1190-5978 |
| authorships[3].author.display_name | Tarek H. Mouhieddine |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[3].affiliations[0].raw_affiliation_string | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[3].institutions[0].id | https://openalex.org/I98704320 |
| authorships[3].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Tarek H. Mouhieddine |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[4].author.id | https://openalex.org/A5072956422 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-0800-5709 |
| authorships[4].author.display_name | Juan Esteban Velez-Hernandez |
| authorships[4].countries | CO, US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[4].affiliations[0].raw_affiliation_string | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I35961687 |
| authorships[4].affiliations[1].raw_affiliation_string | 3Department of Internal Medicine, Universidad de Antioquia, Medellin, Colombia |
| authorships[4].institutions[0].id | https://openalex.org/I35961687 |
| authorships[4].institutions[0].ror | https://ror.org/03bp5hc83 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I35961687 |
| authorships[4].institutions[0].country_code | CO |
| authorships[4].institutions[0].display_name | Universidad de Antioquia |
| authorships[4].institutions[1].id | https://openalex.org/I205783295 |
| authorships[4].institutions[1].ror | https://ror.org/05bnh6r87 |
| authorships[4].institutions[1].type | education |
| authorships[4].institutions[1].lineage | https://openalex.org/I205783295 |
| authorships[4].institutions[1].country_code | US |
| authorships[4].institutions[1].display_name | Cornell University |
| authorships[4].institutions[2].id | https://openalex.org/I4387153466 |
| authorships[4].institutions[2].ror | https://ror.org/02r109517 |
| authorships[4].institutions[2].type | education |
| authorships[4].institutions[2].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[4].institutions[2].country_code | US |
| authorships[4].institutions[2].display_name | Weill Cornell Medicine |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Juan Esteban Velez-Hernandez |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, 3Department of Internal Medicine, Universidad de Antioquia, Medellin, Colombia |
| authorships[5].author.id | https://openalex.org/A5098751611 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Katherine Engles |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[5].affiliations[0].raw_affiliation_string | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[5].institutions[0].id | https://openalex.org/I98704320 |
| authorships[5].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Katherine Engles |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[6].author.id | https://openalex.org/A5029993254 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-5441-1516 |
| authorships[6].author.display_name | Joshua Fein |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[6].affiliations[0].raw_affiliation_string | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[6].institutions[0].id | https://openalex.org/I205783295 |
| authorships[6].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Cornell University |
| authorships[6].institutions[1].id | https://openalex.org/I4387153466 |
| authorships[6].institutions[1].ror | https://ror.org/02r109517 |
| authorships[6].institutions[1].type | education |
| authorships[6].institutions[1].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[6].institutions[1].country_code | US |
| authorships[6].institutions[1].display_name | Weill Cornell Medicine |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Joshua A. Fein |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[7].author.id | https://openalex.org/A5026647971 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-0854-0768 |
| authorships[7].author.display_name | Jorge Monge |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[7].affiliations[0].raw_affiliation_string | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[7].institutions[0].id | https://openalex.org/I205783295 |
| authorships[7].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Cornell University |
| authorships[7].institutions[1].id | https://openalex.org/I4387153466 |
| authorships[7].institutions[1].ror | https://ror.org/02r109517 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[7].institutions[1].country_code | US |
| authorships[7].institutions[1].display_name | Weill Cornell Medicine |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Jorge Monge |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[8].author.id | https://openalex.org/A5023313666 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-3576-9106 |
| authorships[8].author.display_name | Cara A. Rosenbaum |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[8].affiliations[0].raw_affiliation_string | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[8].institutions[0].id | https://openalex.org/I205783295 |
| authorships[8].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Cornell University |
| authorships[8].institutions[1].id | https://openalex.org/I4387153466 |
| authorships[8].institutions[1].ror | https://ror.org/02r109517 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[8].institutions[1].country_code | US |
| authorships[8].institutions[1].display_name | Weill Cornell Medicine |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Cara Rosenbaum |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[9].author.id | https://openalex.org/A5113598256 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Roger Pearse |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[9].affiliations[0].raw_affiliation_string | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[9].institutions[0].id | https://openalex.org/I205783295 |
| authorships[9].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Cornell University |
| authorships[9].institutions[1].id | https://openalex.org/I4387153466 |
| authorships[9].institutions[1].ror | https://ror.org/02r109517 |
| authorships[9].institutions[1].type | education |
| authorships[9].institutions[1].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[9].institutions[1].country_code | US |
| authorships[9].institutions[1].display_name | Weill Cornell Medicine |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Roger Pearse |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[10].author.id | https://openalex.org/A5014718917 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-7938-825X |
| authorships[10].author.display_name | David Jayabalan |
| authorships[10].countries | CO |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I35961687 |
| authorships[10].affiliations[0].raw_affiliation_string | 3Department of Internal Medicine, Universidad de Antioquia, Medellin, Colombia |
| authorships[10].institutions[0].id | https://openalex.org/I35961687 |
| authorships[10].institutions[0].ror | https://ror.org/03bp5hc83 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I35961687 |
| authorships[10].institutions[0].country_code | CO |
| authorships[10].institutions[0].display_name | Universidad de Antioquia |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | David Jayabalan |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | 3Department of Internal Medicine, Universidad de Antioquia, Medellin, Colombia |
| authorships[11].author.id | https://openalex.org/A5008329218 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-4829-1954 |
| authorships[11].author.display_name | Christian Gordillo |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I78577930 |
| authorships[11].affiliations[0].raw_affiliation_string | 4Division of Hematology & Oncology, Columbia University Irving Cancer Center, New York, NY |
| authorships[11].institutions[0].id | https://openalex.org/I78577930 |
| authorships[11].institutions[0].ror | https://ror.org/00hj8s172 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I78577930 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Columbia University |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Christian Gordillo |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | 4Division of Hematology & Oncology, Columbia University Irving Cancer Center, New York, NY |
| authorships[12].author.id | https://openalex.org/A5109504846 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Hei Ton Chan |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I78577930 |
| authorships[12].affiliations[0].raw_affiliation_string | 4Division of Hematology & Oncology, Columbia University Irving Cancer Center, New York, NY |
| authorships[12].institutions[0].id | https://openalex.org/I78577930 |
| authorships[12].institutions[0].ror | https://ror.org/00hj8s172 |
| authorships[12].institutions[0].type | education |
| authorships[12].institutions[0].lineage | https://openalex.org/I78577930 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Columbia University |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Hei Ton Chan |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | 4Division of Hematology & Oncology, Columbia University Irving Cancer Center, New York, NY |
| authorships[13].author.id | https://openalex.org/A5086875969 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-4616-8568 |
| authorships[13].author.display_name | Samuel Yamshon |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[13].affiliations[0].raw_affiliation_string | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[13].institutions[0].id | https://openalex.org/I205783295 |
| authorships[13].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Cornell University |
| authorships[13].institutions[1].id | https://openalex.org/I4387153466 |
| authorships[13].institutions[1].ror | https://ror.org/02r109517 |
| authorships[13].institutions[1].type | education |
| authorships[13].institutions[1].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[13].institutions[1].country_code | US |
| authorships[13].institutions[1].display_name | Weill Cornell Medicine |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Samuel Yamshon |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[14].author.id | https://openalex.org/A5076589550 |
| authorships[14].author.orcid | https://orcid.org/0000-0001-8454-5136 |
| authorships[14].author.display_name | Santiago Thibaud |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[14].affiliations[0].raw_affiliation_string | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[14].institutions[0].id | https://openalex.org/I98704320 |
| authorships[14].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[14].institutions[0].type | education |
| authorships[14].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Santiago Thibaud |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[15].author.id | https://openalex.org/A5002240997 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-8547-8905 |
| authorships[15].author.display_name | Markus Y. Mapara |
| authorships[15].countries | US |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I78577930 |
| authorships[15].affiliations[0].raw_affiliation_string | 4Division of Hematology & Oncology, Columbia University Irving Cancer Center, New York, NY |
| authorships[15].institutions[0].id | https://openalex.org/I78577930 |
| authorships[15].institutions[0].ror | https://ror.org/00hj8s172 |
| authorships[15].institutions[0].type | education |
| authorships[15].institutions[0].lineage | https://openalex.org/I78577930 |
| authorships[15].institutions[0].country_code | US |
| authorships[15].institutions[0].display_name | Columbia University |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Markus Mapara |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | 4Division of Hematology & Oncology, Columbia University Irving Cancer Center, New York, NY |
| authorships[16].author.id | https://openalex.org/A5006640724 |
| authorships[16].author.orcid | https://orcid.org/0000-0001-5566-0864 |
| authorships[16].author.display_name | Giorgio Inghirami |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[16].affiliations[0].raw_affiliation_string | 5Department of Pathology, Weill Cornell Medicine, New York, NY |
| authorships[16].institutions[0].id | https://openalex.org/I205783295 |
| authorships[16].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[16].institutions[0].type | education |
| authorships[16].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | Cornell University |
| authorships[16].institutions[1].id | https://openalex.org/I4387153466 |
| authorships[16].institutions[1].ror | https://ror.org/02r109517 |
| authorships[16].institutions[1].type | education |
| authorships[16].institutions[1].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[16].institutions[1].country_code | US |
| authorships[16].institutions[1].display_name | Weill Cornell Medicine |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Giorgio Inghirami |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | 5Department of Pathology, Weill Cornell Medicine, New York, NY |
| authorships[17].author.id | https://openalex.org/A5031344736 |
| authorships[17].author.orcid | https://orcid.org/0000-0003-1708-7344 |
| authorships[17].author.display_name | Suzanne Lentzsch |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I78577930 |
| authorships[17].affiliations[0].raw_affiliation_string | 4Division of Hematology & Oncology, Columbia University Irving Cancer Center, New York, NY |
| authorships[17].institutions[0].id | https://openalex.org/I78577930 |
| authorships[17].institutions[0].ror | https://ror.org/00hj8s172 |
| authorships[17].institutions[0].type | education |
| authorships[17].institutions[0].lineage | https://openalex.org/I78577930 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | Columbia University |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Suzanne Lentzsch |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | 4Division of Hematology & Oncology, Columbia University Irving Cancer Center, New York, NY |
| authorships[18].author.id | https://openalex.org/A5085167557 |
| authorships[18].author.orcid | https://orcid.org/0000-0003-2185-9546 |
| authorships[18].author.display_name | Ran Reshef |
| authorships[18].countries | US |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I78577930 |
| authorships[18].affiliations[0].raw_affiliation_string | 4Division of Hematology & Oncology, Columbia University Irving Cancer Center, New York, NY |
| authorships[18].institutions[0].id | https://openalex.org/I78577930 |
| authorships[18].institutions[0].ror | https://ror.org/00hj8s172 |
| authorships[18].institutions[0].type | education |
| authorships[18].institutions[0].lineage | https://openalex.org/I78577930 |
| authorships[18].institutions[0].country_code | US |
| authorships[18].institutions[0].display_name | Columbia University |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Ran Reshef |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | 4Division of Hematology & Oncology, Columbia University Irving Cancer Center, New York, NY |
| authorships[19].author.id | https://openalex.org/A5047805762 |
| authorships[19].author.orcid | https://orcid.org/0009-0004-9914-5628 |
| authorships[19].author.display_name | Adriana Rossi |
| authorships[19].countries | US |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[19].affiliations[0].raw_affiliation_string | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[19].institutions[0].id | https://openalex.org/I98704320 |
| authorships[19].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[19].institutions[0].type | education |
| authorships[19].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[19].institutions[0].country_code | US |
| authorships[19].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Adriana Rossi |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[20].author.id | https://openalex.org/A5030726651 |
| authorships[20].author.orcid | https://orcid.org/0000-0001-9694-8469 |
| authorships[20].author.display_name | Samir Parekh |
| authorships[20].countries | US |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[20].affiliations[0].raw_affiliation_string | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[20].institutions[0].id | https://openalex.org/I98704320 |
| authorships[20].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[20].institutions[0].type | education |
| authorships[20].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[20].institutions[0].country_code | US |
| authorships[20].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Samir Parekh |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[21].author.id | https://openalex.org/A5028046297 |
| authorships[21].author.orcid | https://orcid.org/0000-0003-2934-6518 |
| authorships[21].author.display_name | Sundar Jagannath |
| authorships[21].countries | US |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[21].affiliations[0].raw_affiliation_string | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[21].institutions[0].id | https://openalex.org/I98704320 |
| authorships[21].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[21].institutions[0].type | education |
| authorships[21].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[21].institutions[0].country_code | US |
| authorships[21].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Sundar Jagannath |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[22].author.id | https://openalex.org/A5043259076 |
| authorships[22].author.orcid | https://orcid.org/0000-0003-0274-4292 |
| authorships[22].author.display_name | Shambavi Richard |
| authorships[22].countries | US |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[22].affiliations[0].raw_affiliation_string | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[22].institutions[0].id | https://openalex.org/I98704320 |
| authorships[22].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[22].institutions[0].type | education |
| authorships[22].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[22].institutions[0].country_code | US |
| authorships[22].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Shambavi Richard |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | 2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY |
| authorships[23].author.id | https://openalex.org/A5077846750 |
| authorships[23].author.orcid | |
| authorships[23].author.display_name | Rubén Niesvizky |
| authorships[23].countries | US |
| authorships[23].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[23].affiliations[0].raw_affiliation_string | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[23].institutions[0].id | https://openalex.org/I205783295 |
| authorships[23].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[23].institutions[0].type | education |
| authorships[23].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[23].institutions[0].country_code | US |
| authorships[23].institutions[0].display_name | Cornell University |
| authorships[23].institutions[1].id | https://openalex.org/I4387153466 |
| authorships[23].institutions[1].ror | https://ror.org/02r109517 |
| authorships[23].institutions[1].type | education |
| authorships[23].institutions[1].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[23].institutions[1].country_code | US |
| authorships[23].institutions[1].display_name | Weill Cornell Medicine |
| authorships[23].author_position | middle |
| authorships[23].raw_author_name | Ruben Niesvizky |
| authorships[23].is_corresponding | False |
| authorships[23].raw_affiliation_strings | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[24].author.id | https://openalex.org/A5003087873 |
| authorships[24].author.orcid | https://orcid.org/0000-0002-4652-5449 |
| authorships[24].author.display_name | Mark Bustoros |
| authorships[24].countries | US |
| authorships[24].affiliations[0].institution_ids | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[24].affiliations[0].raw_affiliation_string | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| authorships[24].institutions[0].id | https://openalex.org/I205783295 |
| authorships[24].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[24].institutions[0].type | education |
| authorships[24].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[24].institutions[0].country_code | US |
| authorships[24].institutions[0].display_name | Cornell University |
| authorships[24].institutions[1].id | https://openalex.org/I4387153466 |
| authorships[24].institutions[1].ror | https://ror.org/02r109517 |
| authorships[24].institutions[1].type | education |
| authorships[24].institutions[1].lineage | https://openalex.org/I205783295, https://openalex.org/I4387153466 |
| authorships[24].institutions[1].country_code | US |
| authorships[24].institutions[1].display_name | Weill Cornell Medicine |
| authorships[24].author_position | last |
| authorships[24].raw_author_name | Mark Bustoros |
| authorships[24].is_corresponding | False |
| authorships[24].raw_affiliation_strings | 1Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1182/bloodadvances.2023012470 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2024-05-23T00:00:00 |
| display_name | Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11491 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | CAR-T cell therapy research |
| related_works | https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166, https://openalex.org/W1489783725, https://openalex.org/W2148612803 |
| cited_by_count | 14 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 13 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1182/bloodadvances.2023012470 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764683450 |
| best_oa_location.source.issn | 2473-9529, 2473-9537 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2473-9529 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Blood Advances |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_lineage_names | Elsevier BV |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Blood Advances |
| best_oa_location.landing_page_url | https://doi.org/10.1182/bloodadvances.2023012470 |
| primary_location.id | doi:10.1182/bloodadvances.2023012470 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2764683450 |
| primary_location.source.issn | 2473-9529, 2473-9537 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2473-9529 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Blood Advances |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_lineage_names | Elsevier BV |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Blood Advances |
| primary_location.landing_page_url | https://doi.org/10.1182/bloodadvances.2023012470 |
| publication_date | 2024-05-22 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W4319812103, https://openalex.org/W4379375986, https://openalex.org/W3176532045, https://openalex.org/W3133229959, https://openalex.org/W4321598916, https://openalex.org/W4200487716, https://openalex.org/W4362614405, https://openalex.org/W4313406551, https://openalex.org/W2342423058, https://openalex.org/W4210589143, https://openalex.org/W3156422132, https://openalex.org/W2905654445, https://openalex.org/W4385191703, https://openalex.org/W2486629951, https://openalex.org/W4380203720, https://openalex.org/W2119147717, https://openalex.org/W4387900511, https://openalex.org/W4390637173, https://openalex.org/W2598700764 |
| referenced_works_count | 19 |
| abstract_inverted_index.6 | 117 |
| abstract_inverted_index.P | 119, 154 |
| abstract_inverted_index.T | 8 |
| abstract_inverted_index.a | 19, 111, 137, 204 |
| abstract_inverted_index.15 | 67 |
| abstract_inverted_index.In | 157 |
| abstract_inverted_index.MM | 77 |
| abstract_inverted_index.We | 219 |
| abstract_inverted_index.an | 215 |
| abstract_inverted_index.as | 214 |
| abstract_inverted_index.be | 212 |
| abstract_inverted_index.in | 12, 21, 64, 72, 242, 245 |
| abstract_inverted_index.is | 203 |
| abstract_inverted_index.of | 24, 41, 59, 97, 173, 192, 230 |
| abstract_inverted_index.to | 36, 221 |
| abstract_inverted_index.vs | 116 |
| abstract_inverted_index.× | 108, 127, 134, 162 |
| abstract_inverted_index.156 | 73 |
| abstract_inverted_index.95% | 150 |
| abstract_inverted_index.ALC | 92, 202, 231 |
| abstract_inverted_index.DoR | 176 |
| abstract_inverted_index.MM. | 249 |
| abstract_inverted_index.PFS | 113, 146, 174 |
| abstract_inverted_index.R/R | 248 |
| abstract_inverted_index.and | 28, 39, 56, 85, 102, 144, 164, 175, 189, 210, 239 |
| abstract_inverted_index.are | 16 |
| abstract_inverted_index.but | 44 |
| abstract_inverted_index.can | 211 |
| abstract_inverted_index.for | 179, 206, 224 |
| abstract_inverted_index.had | 94, 110 |
| abstract_inverted_index.has | 33 |
| abstract_inverted_index.its | 240 |
| abstract_inverted_index.our | 196, 222 |
| abstract_inverted_index.the | 22, 54, 65, 80, 169, 190, 225, 228 |
| abstract_inverted_index.(MM) | 15 |
| abstract_inverted_index.3.4; | 149 |
| abstract_inverted_index.BCMA | 207, 233 |
| abstract_inverted_index.DoR. | 103 |
| abstract_inverted_index.This | 50 |
| abstract_inverted_index.age, | 184 |
| abstract_inverted_index.been | 34 |
| abstract_inverted_index.data | 199 |
| abstract_inverted_index.days | 68 |
| abstract_inverted_index.flow | 197 |
| abstract_inverted_index.only | 170 |
| abstract_inverted_index.that | 201 |
| abstract_inverted_index.this | 46 |
| abstract_inverted_index.time | 227 |
| abstract_inverted_index.used | 11, 213 |
| abstract_inverted_index.were | 168 |
| abstract_inverted_index.with | 75, 79, 89, 105, 123, 125, 131, 140, 236, 247 |
| abstract_inverted_index.(30.5 | 114 |
| abstract_inverted_index.(ALC) | 63 |
| abstract_inverted_index.(R/R) | 26 |
| abstract_inverted_index..001) | 121 |
| abstract_inverted_index.CAR-T | 29, 70, 185, 208, 234 |
| abstract_inverted_index.after | 31, 69, 177, 232 |
| abstract_inverted_index.cells | 9 |
| abstract_inverted_index.count | 62 |
| abstract_inverted_index.depth | 38, 96 |
| abstract_inverted_index.early | 141 |
| abstract_inverted_index.first | 66, 226 |
| abstract_inverted_index.group | 139 |
| abstract_inverted_index.short | 145 |
| abstract_inverted_index.shown | 35 |
| abstract_inverted_index.study | 52 |
| abstract_inverted_index.those | 124 |
| abstract_inverted_index.(DoR), | 43 |
| abstract_inverted_index.(PFS), | 101 |
| abstract_inverted_index..001). | 156 |
| abstract_inverted_index.2-5.8; | 153 |
| abstract_inverted_index.ALCmax | 106, 132, 160 |
| abstract_inverted_index.B-cell | 1 |
| abstract_inverted_index.agents | 82 |
| abstract_inverted_index.better | 95 |
| abstract_inverted_index.higher | 90 |
| abstract_inverted_index.impact | 58 |
| abstract_inverted_index.inform | 37 |
| abstract_inverted_index.lines. | 194 |
| abstract_inverted_index.months | 115 |
| abstract_inverted_index.number | 191 |
| abstract_inverted_index.ratio, | 148 |
| abstract_inverted_index.≤0.5 | 133 |
| abstract_inverted_index.≤1.0 | 126 |
| abstract_inverted_index.(hazard | 147 |
| abstract_inverted_index.103/μL | 109, 135, 163 |
| abstract_inverted_index.antigen | 3, 6 |
| abstract_inverted_index.disease | 142, 167 |
| abstract_inverted_index.marker. | 218 |
| abstract_inverted_index.maximum | 91 |
| abstract_inverted_index.months; | 118 |
| abstract_inverted_index.myeloma | 14 |
| abstract_inverted_index.process | 47 |
| abstract_inverted_index.rapidly | 17 |
| abstract_inverted_index.remains | 48 |
| abstract_inverted_index.report, | 220 |
| abstract_inverted_index.staging | 181 |
| abstract_inverted_index.suggest | 200 |
| abstract_inverted_index.treated | 78 |
| abstract_inverted_index.utility | 241 |
| abstract_inverted_index.whereas | 129 |
| abstract_inverted_index.&lt; | 120, 155 |
| abstract_inverted_index.(ALCmax) | 93 |
| abstract_inverted_index.(CAR-Ts) | 10 |
| abstract_inverted_index.103/μL, | 128 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Patients | 88, 104 |
| abstract_inverted_index.absolute | 60 |
| abstract_inverted_index.becoming | 18 |
| abstract_inverted_index.chimeric | 5 |
| abstract_inverted_index.clinical | 237 |
| abstract_inverted_index.compared | 122 |
| abstract_inverted_index.disease, | 27 |
| abstract_inverted_index.duration | 40 |
| abstract_inverted_index.infusion | 32, 71, 235 |
| abstract_inverted_index.kinetics | 55 |
| abstract_inverted_index.mainstay | 20 |
| abstract_inverted_index.multiple | 13 |
| abstract_inverted_index.outcomes | 238 |
| abstract_inverted_index.patients | 74, 130, 246 |
| abstract_inverted_index.previous | 193 |
| abstract_inverted_index.product, | 186 |
| abstract_inverted_index.receptor | 7 |
| abstract_inverted_index.relapsed | 76 |
| abstract_inverted_index.response | 42, 244 |
| abstract_inverted_index.staging, | 183 |
| abstract_inverted_index.superior | 112 |
| abstract_inverted_index.survival | 100 |
| abstract_inverted_index.systemic | 182 |
| abstract_inverted_index.Moreover, | 195 |
| abstract_inverted_index.analysis, | 159 |
| abstract_inverted_index.cytometry | 198 |
| abstract_inverted_index.describes | 53 |
| abstract_inverted_index.expansion | 30, 209 |
| abstract_inverted_index.high-risk | 138, 187 |
| abstract_inverted_index.interval, | 152 |
| abstract_inverted_index.measuring | 45 |
| abstract_inverted_index.represent | 136 |
| abstract_inverted_index.response, | 98 |
| abstract_inverted_index.surrogate | 205 |
| abstract_inverted_index.treatment | 23 |
| abstract_inverted_index.accessible | 216 |
| abstract_inverted_index.accounting | 178 |
| abstract_inverted_index.autoleucel | 84 |
| abstract_inverted_index.confidence | 151 |
| abstract_inverted_index.knowledge, | 223 |
| abstract_inverted_index.lymphocyte | 61 |
| abstract_inverted_index.maturation | 2 |
| abstract_inverted_index.predicting | 243 |
| abstract_inverted_index.predictors | 172 |
| abstract_inverted_index.prognostic | 57, 217 |
| abstract_inverted_index.vicleucel. | 87 |
| abstract_inverted_index.&gt;1.0 | 107, 161 |
| abstract_inverted_index.association | 229 |
| abstract_inverted_index.independent | 171 |
| abstract_inverted_index.multicenter | 51 |
| abstract_inverted_index.progression | 143 |
| abstract_inverted_index.idecabtagene | 86 |
| abstract_inverted_index.multivariate | 158 |
| abstract_inverted_index.cytogenetics, | 188 |
| abstract_inverted_index.international | 180 |
| abstract_inverted_index.BCMA-targeting | 81 |
| abstract_inverted_index.ciltacabtagene | 83 |
| abstract_inverted_index.extramedullary | 166 |
| abstract_inverted_index.nonparaskeletal | 165 |
| abstract_inverted_index.investigational. | 49 |
| abstract_inverted_index.progression-free | 99 |
| abstract_inverted_index.(BCMA)–targeting | 4 |
| abstract_inverted_index.relapsed/refractory | 25 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 90 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 25 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.5799999833106995 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.96719645 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |